Vaccines to prevent hepatitis B and hepatitis A virus infections - PubMed

Affiliations

• PMID: 2155262

Review

Vaccines to prevent hepatitis B and hepatitis A virus infections

S C Hadler. Infect Dis Clin North Am. 1990 Mar.

Abstract

Vaccines to prevent hepatitis B infection became available in 1982, and were recommended primarily for adults considered at high risk because of exposure in the workplace or lifestyles that lead to sexual or parenteral exposure to the virus. Plasma-derived and recombinant vaccines produced in yeast are highly immunogenic, safe, and effective for all age groups. Decreased response and protection by vaccine occur in older persons and in persons with immunosuppressive illnesses. The main issues concerning current vaccination programs include the possible use of lower doses to reduce the cost of the vaccine, the duration of protection and need for vaccine booster doses, and the need for postvaccination testing in hospitals. The failure of current vaccination programs to decrease disease incidence, a matter of great concern nationally, can be ascribed to failure to deliver vaccine to the groups at highest risk. More effective strategies for control, including the universal vaccination of infants or adolescents, must now be examined. Newer vaccines that incorporate other viral antigens and that may offer increased efficacy are being developed. Vaccines to prevent hepatitis A--both killed and live attenuated vaccines--are undergoing clinical trials and may become available in the next 5 years.

Similar articles

• [Prevention of hepatitis A and hepatitis B by vaccination].

  Buisson Y, Meyran M. Buisson Y, et al. Ann Gastroenterol Hepatol (Paris). 1995 Oct;31(5):306-8; discussion 308-9. Ann Gastroenterol Hepatol (Paris). 1995. PMID: 8572566 French.

• [Viral hepatitis and immunoprophylaxis].

  Deinhardt F, Jilg W. Deinhardt F, et al. Zentralbl Bakteriol Mikrobiol Hyg B. 1985 Feb;180(2-3):134-45. Zentralbl Bakteriol Mikrobiol Hyg B. 1985. PMID: 2986380 Review. German.

• [Prevention of hepatitis A and hepatitis B with vaccination].

  Buisson Y, Meyran M. Buisson Y, et al. Bull Acad Natl Med. 1995 Feb;179(2):367-74; discussion 373-5. Bull Acad Natl Med. 1995. PMID: 7614064 French.

• Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges.

  Mele A, Tosti ME, Mariano A, Pizzuti R, Ferro A, Borrini B, Zotti C, Lopalco P, Curtale F, Balocchini E, Spada E; National Surveillance System for Acute Viral Hepatitis (SEIEVA) Collaborating Group. Mele A, et al. Clin Infect Dis. 2008 Mar 15;46(6):868-75. doi: 10.1086/528687. Clin Infect Dis. 2008. PMID: 18269332

• [Practical considerations of immunoprophylaxis in viral hepatitis].

  Nemesánszky E, Csepregi A. Nemesánszky E, et al. Orv Hetil. 1998 Aug 2;139(31):1835-42. Orv Hetil. 1998. PMID: 9729677 Review. Hungarian.

Cited by

• No evidence for occult HBV infection in hepatitis B vaccine non-responders.

  Aghasadeghi MR, Banifazl M, Aghakhani A, Eslamifar A, Vahabpour R, Ramezani A. Aghasadeghi MR, et al. Iran J Microbiol. 2014 Oct;6(5):350-3. Iran J Microbiol. 2014. PMID: 25848527 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information